- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05128487
A Study of NDI 1150-101 in Patients With Solid Tumors
March 28, 2024 updated by: Nimbus Saturn, Inc.
A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of NDI-101150 Administered as Monotherapy or in Combination With Pembrolizumab in Patients With Solid Tumors
This study is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) and to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of NDI-101150 given as monotherapy or in combination with pembrolizumab in adult patients with advanced solid tumors.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter, open-label, first-in-human, Phase 1/2 study.
The study will consist of 2 phases:
- The Dose Escalation Phase: designed to evaluate the safety and tolerability of NDI-101150 as monotherapy (Arm 1) and in combination with pembrolizumab (Arm 2) in patients with advanced solid tumors.
- The Dose Expansion Phase: designed to evaluate the safety and efficacy of NDI-101150 as monotherapy (Arm 1) and in combination with pembrolizumab (Arm 2) in disease-specific dose expansion cohorts: gastric and gastroesophageal junction [GEJ] cancer, non-small cell lung cancer [NSCLC], and renal cell carcinoma [RCC].
Each phase of the study will consist of 3 periods:
- A Screening period of up to 28 days during which patient eligibility will be reviewed and approved by the Sponsor.
- Treatment period that will extend from Cycle 1 Day 1 until progression of disease (PD), unacceptable toxicity, withdrawal of consent, start of a new systemic anticancer treatment, discontinuation of the patient by the Investigator, or termination of the study by the Sponsor. This will also include Safety Follow-up Visit 30 days [+3 days] after the last dose of investigational medicinal product.
- Post treatment Follow-up period which will continue until lost to follow-up, withdrawal of consent, or the End of the Study (whichever comes first).
Study Type
Interventional
Enrollment (Estimated)
106
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Study Coordinator
- Phone Number: 8579992009
- Email: clinical@nimbustx.com
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85258
- Recruiting
- Honor Health Research Institute
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007-2113
- Recruiting
- Georgetown University
-
-
Florida
-
Ocala, Florida, United States, 34474
- Recruiting
- Ocala Oncology Center
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Recruiting
- Norton Cancer Institute
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Recruiting
- University of Maryland Greenebaum Comprehensive Cancer Center
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Recruiting
- Henry Ford Cancer
-
-
Minnesota
-
Saint Paul, Minnesota, United States, 55101
- Recruiting
- HealthPartners Cancer Research Center
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Recruiting
- Hackensack University
-
-
New York
-
New York, New York, United States, 10032
- Recruiting
- Columbia University Irving Medical Center
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Recruiting
- Gabrail Cancer Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Recruiting
- Stephenson Cancer Center
-
-
Texas
-
Dallas, Texas, United States, 75246
- Recruiting
- Texas Oncology - Baylor Charles A. Sammons Cancer Center
-
Houston, Texas, United States, 77030
- Recruiting
- Oncology Consultants
-
Houston, Texas, United States, 77030
- Recruiting
- Center for Oncology and Blood Disorders
-
San Antonio, Texas, United States, 78229
- Recruiting
- NEXT Oncology
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Recruiting
- NEXT Oncology
-
-
Washington
-
Tacoma, Washington, United States, 98405
- Recruiting
- Northwest Medical Specialties
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53705
- Recruiting
- University of Wisconsin
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- Life expectancy of ≥ 12 weeks
- Measurable or non-measurable disease for Dose Escalation; measurable disease using RECIST v1.1 is required for Dose Expansion
- Recovered from prior therapy to Grade ≤ 1 or return to baseline status (except for alopecia)
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Patients with adequate bone marrow, kidney and liver function
- Last dose of previous anticancer therapy ≥ 4 weeks prior to first dose of NDI-101150; includes prior anti-PD-1 or anti-PD-L1 therapy, other anticancer therapy, radiotherapy, or surgical intervention
- For Dose Escalation Phase Only (Dose Escalation, Monotherapy and Combination Therapy): Histologically or cytologically confirmed advanced or metastatic solid tumors for whom no standard therapies are available or refractory to standard therapy
- For Dose Expansion Phase (Dose Expansion, Monotherapy and Combination Therapy): Willing to consent to required tumor biopsy(ies). Histologically or cytologically confirmed advanced or metastatic G/GEJ, NSCLC or RCC for which no standard therapy is available or are refractory to standard therapy
Key Exclusion Criteria:
- Previous solid organ or hematopoietic cell transplant
- Central nervous system (CNS) malignant disease not previously treated, active leptomeningeal disease, uncontrolled symptomatic CNS involvement, or CNS malignant disease requiring steroid or other therapeutic intervention
- Prior anticancer therapy within 2-6 weeks of trial start (depending on nature of therapy).
- Clinically significant cardiovascular disease
- History of severe hypersensitivity reaction to treatment with monoclonal antibody(ies) (for combination therapy cohorts only)
- History of interstitial lung disease, idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of history of pneumonitis on chest computed tomography scan in the last 6 months
- Known additional malignancy that is active and/or in progression requiring treatment
- Unstable or severe uncontrolled medical condition (e.g., unstable cardiac function, unstable pulmonary condition, uncontrolled diabetes, thromboembolic event within the past 3 months) or any important medical or psychiatric illness or abnormal laboratory finding
- Unable to discontinue medications that are strong inducers or inhibitors of CYP3A4 and/or CYP2C8
- History of severe irAE that led to permanent discontinuation of prior immunotherapy
- History of recent Grade >/= 3 irAE or any Grade 4 life-threatening irAE, neurologic or ocular AE of any grade while receiving prior immunotherapy
NOTE: Other protocol defined Inclusion and Exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NDI-101150 (Monotherapy)
Patients in escalation and expansion, will receive NDI-101150 capsules orally once daily continuously in 4-week cycles (28 days).
|
NDI-101150 capsules
|
Experimental: NDI-101150-Pembrolizumab (Combination therapy)
Patients in escalation and expansion phase, will receive NDI-101150 capsules orally once daily continuously in 3-week cycles (21 days), along with pembrolizumab via intravenous (IV) infusion at a dose of 200 mg every 3 weeks.
|
NDI-101150 capsules
Pembrolizumab IV infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Part 1: Frequency of dose-limiting toxicities (DLTs)
Time Frame: Cycle 1 (28 days)
|
Cycle 1 (28 days)
|
Part 2: Objective response rate (ORR)
Time Frame: Up to approximately 34 months
|
Up to approximately 34 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Part 1 and Part 2: Number of patients with adverse events (AEs) and Serious adverse events (SAEs)
Time Frame: From Screening (Day -28 to Day -1) until safety follow-up (>30 days after last dose) [Assessed up to 37 months]
|
From Screening (Day -28 to Day -1) until safety follow-up (>30 days after last dose) [Assessed up to 37 months]
|
Part 1 and Part 2: Maximum plasma concentration (Cmax) of NDI-101150
Time Frame: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 1 Day 2, Cycle 2 Day 2 (Monotherapy); at EOT (end-of-treatment)/ET (early termination) [Cycle length is 28 days for monotherapy and 21 days for combination therapy] (Up to 37 months)
|
Cycle 1 Day 1, Cycle 2 Day 1, Cycle 1 Day 2, Cycle 2 Day 2 (Monotherapy); at EOT (end-of-treatment)/ET (early termination) [Cycle length is 28 days for monotherapy and 21 days for combination therapy] (Up to 37 months)
|
Part 1 and Part 2: Time to maximum plasma concentration (tmax) of NDI-101150
Time Frame: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 1 Day 2, Cycle 2 Day 2 (Monotherapy); at EOT (end-of-treatment)/ET (early termination) [Cycle length is 28 days for monotherapy and 21 days for combination therapy] (Up to 37 months)
|
Cycle 1 Day 1, Cycle 2 Day 1, Cycle 1 Day 2, Cycle 2 Day 2 (Monotherapy); at EOT (end-of-treatment)/ET (early termination) [Cycle length is 28 days for monotherapy and 21 days for combination therapy] (Up to 37 months)
|
Part 1 and Part 2: Area under the concentration-time curve from time zero to the last observable concentration (AUC0-t) of NDI-101150
Time Frame: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 1 Day 2, Cycle 2 Day 2 (Monotherapy); at EOT (end-of-treatment)/ET (early termination) [Cycle length is 28 days for monotherapy and 21 days for combination therapy] (Up to 37 months)
|
Cycle 1 Day 1, Cycle 2 Day 1, Cycle 1 Day 2, Cycle 2 Day 2 (Monotherapy); at EOT (end-of-treatment)/ET (early termination) [Cycle length is 28 days for monotherapy and 21 days for combination therapy] (Up to 37 months)
|
Part 1 and Part 2: Area under the concentration-time curve extrapolated to infinity (AUC0-∞) of NDI-101150
Time Frame: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 1 Day 2, Cycle 2 Day 2 (Monotherapy); at EOT (end-of-treatment)/ET (early termination) [Cycle length is 28 days for monotherapy and 21 days for combination therapy] (Up to 37 months)
|
Cycle 1 Day 1, Cycle 2 Day 1, Cycle 1 Day 2, Cycle 2 Day 2 (Monotherapy); at EOT (end-of-treatment)/ET (early termination) [Cycle length is 28 days for monotherapy and 21 days for combination therapy] (Up to 37 months)
|
Part 1: Objective response rate (ORR)
Time Frame: Assessed up to 37 months
|
Assessed up to 37 months
|
Part 1 and Part 2: Progression-free survival (PFS)
Time Frame: From first dose until confirmed progression of disease (PD) or death (Assessed up to 37 months)
|
From first dose until confirmed progression of disease (PD) or death (Assessed up to 37 months)
|
Part 1 and Part 2: Duration of response (DOR)
Time Frame: Time from first response until confirmed PD (Assessed up to 37 months)
|
Time from first response until confirmed PD (Assessed up to 37 months)
|
Part 1 and Part 2: Time to response (TTR)
Time Frame: Time from first dose until first response (Assessed up to 37 months)
|
Time from first dose until first response (Assessed up to 37 months)
|
Part 2: Overall survival
Time Frame: Assessed up to 37 months
|
Assessed up to 37 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Bhaskar Srivastava, MD, Nimbus Saturn
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 5, 2021
Primary Completion (Estimated)
September 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
October 22, 2021
First Submitted That Met QC Criteria
November 9, 2021
First Posted (Actual)
November 22, 2021
Study Record Updates
Last Update Posted (Actual)
March 29, 2024
Last Update Submitted That Met QC Criteria
March 28, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1150-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Jazz PharmaceuticalsMerck Sharp & Dohme LLCRecruitingAdvanced Solid Tumor | Metastatic Solid TumorUnited States
-
PharmaEngineNot yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor
Clinical Trials on NDI-101150
-
University of Illinois at ChicagoNational Institute of Nursing Research (NINR); Kamuzu College of Nursing, University...CompletedHIV CDC Category A1Malawi
-
TakedaNimbus Lakshmi, Inc.CompletedPsoriatic ArthritisUnited States, Czechia, Germany, Poland
-
TakedaNimbus Lakshmi, Inc.; Innovaderm Research Inc.CompletedModerate to Severe Plaque PsoriasisUnited States, Canada
-
Cairo UniversityEnrolling by invitation
-
Cairo UniversityRecruitingHorizontal Atrophy of Edentulous Alveolar RidgeEgypt
-
Cairo UniversityNot yet recruitingMechanical Neck Pain
-
Gilead SciencesNimbus ApolloCompletedPD Effects of GS-0976 (NDI-010976) on Fractional DNLUnited States
-
Hormozgan University of Medical SciencesCompletedNocturnal EnuresisIran, Islamic Republic of